Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC
Clinical trial NCT06908733 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06908733
- Sponsor
- Liaoning Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-31
- Primary completion
- 2027-09-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.